Mepolizumab

SAN DIEGO — Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and 2023, according to a poster presented here.

SAN DIEGO — Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not alter the benefits of mepolizumab on nasal polyp and VAS scores, according to a presentation here.

SAN DIEGO — Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, as well as with discontinuations, according to a series of posters presented here.

SAN DIEGO — Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used benralizumab, according to a poster presented here.

SAN DIEGO — Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.

In this video, Rula Hajj-Ali, MD discusses the latest developments in the study and treatment of vasculitis.

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was deemed “best predictor” of 12-month remission in patients with severe eosinophilic asthma, according to study data.

BOSTON — Patients with obesity and asthma may see reductions in exacerbations with biologic treatment, according to a presentation at the CHEST Annual Meeting.

The FDA has accepted to review a supplemental new drug application for mepolizumab, an anti-IL-5 biologic, for treating patients with COPD plus an eosinophilic phenotype, according to a GSK press release.

BOSTON — Patients taking benralizumab experienced more asthma exacerbations than patients taking mepolizumab, according to an abstract presented at the CHEST Annual Meeting.